Carcinocinoembryonic
antigen-related
cell adhesion molecule 6 (CEACAM6) is overexpressed in a number of human
malignancies, especially in
pancreatic cancer. It has been demonstrated that CEACAM6 is a potential target for
monoclonal antibody (mAb)
therapy with a safe therapeutic index. Here, we labeled three anti-CEACAM6
antibodies of different sizes, including a
single-domain antibody 2A3 (16 kDa), a heavy chain antibody 2A3-mFc (80 kDa) and a full length antibody 9A6 (150 kDa), with ⁶⁴Cu to image CEACAM6 expression in a xenografted pancreatic
tumor model. For positron emission tomography (PET) imaging, the
tumor mice were intravenously injected with ⁶⁴Cu-
DOTA-
antibodies and static scans were obtained at 5 min, 0.5, 1, 2, 4, 8 and 24h post-injection (p.i.). All three
antibodies showed strong CEACAM6 binding. Ex vivo immunostaining on
tumor sections at 24 h after Ab injection demonstrated specific
tumor targeting of both 2A3-mFc and 9A6. ⁶⁴Cu-DOTA-2A3 showed fast BxPC3
tumor uptake and rapid whole-body clearance. At 24 h p.i., the
tumor uptakes were 98.2±6.12%ID/g for ⁶⁴Cu-DOTA-2A3-mFc and 57.8±3.73%ID/g for ⁶⁴Cu-DOTA-9A6, respectively. Compared with the full length antibody 9A6, the heavy chain antibody 2A3-mFc showed higher
tumor uptake, lower liver uptake and shorter circulation half-life. All the data supported that the heavy chain antibody 2A3-mFc is superior to the
single domain antibody and the full-length antibody with regard to
tumor detection and pharmacokinetics, which has great potential to be developed for CEACAM6-targeted
pancreatic cancer imaging and
therapy.